相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Biochemistry & Molecular Biology
Yu Gao et al.
Summary: This study found that SARS-CoV-2 spike-specific CD4(+) and CD8(+) T cells induced by prior infection or BNT162b2 vaccination provide extensive immune coverage against the Omicron variant. Additionally, T cells induced by BNT162b2 vaccination exhibit higher cross-reactivity to the Omicron variant compared to T cells induced by prior SARS-CoV-2 infection.
Article
Medicine, General & Internal
E. B. Walter et al.
Summary: A regimen of two 10-mu g doses of BNT162b2 administered 21 days apart was found to be safe, immunogenic, and efficacious in children aged 5 to 11 years.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Davide Giavarina et al.
Summary: Although recalculating concentrations based on the NIBSC 20/136 standardization improves analytical and diagnostic comparability, it does not eliminate differences between different methods, as recalibrated results still vary in terms of tendency and individual data points.
Article
Immunology
Susan M. Bueno et al.
Summary: Vaccination with CoronaVac in Chilean adults aged >= 18 years is safe and induces immune responses, including antibody production and T cell activation. The vaccine demonstrates the generation of neutralizing antibodies and T cell responses in both the 18-59 and >= 60 age groups.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Virology
Jorge Fernandez et al.
Summary: After receiving two doses of CoronaVac vaccine, individuals showed lower neutralization potency against alpha and gamma variants compared to the D614G variant. Some plasma samples did not demonstrate efficient neutralization against alpha and gamma variants, suggesting these variants might evade neutralization by antibodies elicited from vaccination. Robust genomic and biological surveillance of viral variants is crucial for developing effective strategies to control SARS-CoV-2.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Immunology
Justyna Sieber et al.
Summary: Children infected with SARS-CoV-2 generate long-lasting antibody and T cell responses for over 12 months, but these responses have poor neutralizing activity against the omicron variant. However, vaccination of pre-immune children significantly improves the omicron-neutralizing capacity.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Microbiology
Monica L. Acevedo et al.
Summary: The SARS-CoV-2 Lambda variant is prevalent in Latin America. Antibodies generated by CoronaVac and BNT162b2 were analyzed for their neutralizing capacity against SARS-CoV-2 Lambda in plasma samples from healthcare workers and patients in Chile. The study found that BNT162b2 elicits higher neutralizing antibody titres compared to CoronaVac. The study also identified mutations in the Lambda variant's spike protein that may contribute to immune escape.
NATURE MICROBIOLOGY
(2022)
Article
Medicine, General & Internal
Leonardo Vargas et al.
Summary: This study compares the immunogenicity and time course of the humoral response elicited by the CoronaVac vaccine with homologous and heterologous boosters. The results show that CoronaVac induces lower levels of antibodies compared to the BNT162b2 vaccine, but the response can be greatly enhanced with a heterologous booster scheme. Additionally, both homologous and heterologous boosters induce a durable antibody response that remains effective after 3 months.
Article
Microbiology
Barbara M. Schultz et al.
Summary: This study reports the impact of a booster dose of CoronaVac on the immune response against Delta and Omicron variants. Four weeks after the booster dose, there was a significant increase in neutralizing antibodies, and specific T cells reached their peak. Furthermore, the immune response induced by the booster showed activity against Delta and Omicron variants.
Article
Infectious Diseases
Zhiwei Wu et al.
Summary: The study showed that CoronaVac vaccine is safe and well tolerated in older adults, and is able to induce neutralizing antibody levels. The highest dose of 3 μg of the vaccine can generate neutralizing antibody levels similar to the 6 μg dose, supporting the use of the 3 μg dose CoronaVac in phase 3 trials.
LANCET INFECTIOUS DISEASES
(2021)
Article
Infectious Diseases
Yanjun Zhang et al.
Summary: This study investigated the safety, tolerability, and immunogenicity of the COVID-19 vaccine candidate CoronaVac, and found that the 3 μg dose showed higher seroconversion rates in the phase 2 trial.
LANCET INFECTIOUS DISEASES
(2021)
Article
Multidisciplinary Sciences
Carolina Beltran-Pavez et al.
Summary: Chile has one of the worst numbers worldwide in terms of SARS-CoV-2 positive cases and COVID-19-related deaths per million inhabitants; characterization of neutralizing antibody (NAb) responses in the general population is critical to understanding immunity at the local level. The study found samples with decreased or enhanced neutralization activity against the D614G spike variant, indicating its relevance in host immunity. These data provide the first insights into NAb responses in individuals from Chile, serving as a guide for future studies in the country.
Article
Medical Laboratory Technology
Christian Irsara et al.
Summary: The clinical performance of the Siemens sCOVG assay was evaluated, with specificity of 99.4% and sensitivity of 90.5%. S1-RBD antibody levels showed good correlation with virus neutralization titers, serving as a surrogate for neutralizing capacity. Levels of S1-RBD IgG increase with age, with significantly higher levels observed in hospitalized COVID-19 patients compared to outpatients.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2021)
Article
Immunology
Felipe Melo-Gonzalez et al.
Summary: Vaccination with CoronaVac promotes the secretion of antibodies capable of blocking SARS-CoV-2 variants of concern and partially neutralizing SARS-CoV-2 infection. Additionally, it stimulates cellular responses against all variants of concern.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Infectious Diseases
Bihua Han et al.
Summary: The study evaluated the safety, tolerability, and immunogenicity of the candidate COVID-19 vaccine CoronaVac containing inactivated SARS-CoV-2 in children and adolescents aged 3-17 years. The research findings indicate that the 3.0 μg dose induced higher levels of neutralizing antibodies compared to the 1.5 μg dose, supporting the use of the 3.0 μg dose for further studies in this age group.
LANCET INFECTIOUS DISEASES
(2021)
News Item
Multidisciplinary Sciences
Smriti Mallapaty
Article
Medicine, General & Internal
Kashif Ali et al.
Summary: The study demonstrates that the mRNA-1273 vaccine has good safety profile in adolescents aged 12 to 17 years, with immune response similar to that in young adults. It also proves the efficacy of the vaccine in preventing Covid-19 in this age group.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Carolyn A. Cohen et al.
Summary: This study shows that infected children have lower CD4(+) and CD8(+) T cell responses to SARS-CoV-2 proteins compared to infected adults. Children also have reduced CD4(+) T cell effector memory but comparable T cell polyfunctionality.
NATURE COMMUNICATIONS
(2021)
Article
Cell Biology
Alison Tarke et al.
Summary: The study showed that SARS-CoV-2 variants do not significantly disrupt total T cell reactivity, although decreases in response frequency of 10%-22% were observed under certain assay/VOC combinations. This underscores the importance of actively monitoring T cell responses in the context of SARS-CoV-2 evolution.
CELL REPORTS MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Alba Grifoni et al.
Article
Multidisciplinary Sciences
Qiang Gao et al.
Editorial Material
Medicine, General & Internal
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2013)
